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Gemcitabine, 20-deoxy-20 ,20-diﬂuorocytidine, is currently prescribed against a number of cancers. Here
we report a linear synthesis of gemcitabine with a high-yielding direct conversion of 3,5-di-O-benzoyl-2-
deoxy-2,2-diﬂuororibose into the corresponding glycosyl urea as the key step, followed by conventional
conversion to the cytosine base via the uracil derivative. The process proceeded with modest anomeric
selectivity.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).O LG
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Scheme 1. Convergent nucleobase introduction in the synthesis of gemcitabine 1.1. Introduction
Gemcitabine 1 (Scheme 1), marketed by its discoverer Lilly as
the HCl salt under the trade name of Gemzar, is a widely prescribed
anticancer drug against pancreatic, ovarian and breast cancer.
Before its recent patent expiry, it was a $1 bn dollar per annum
drug, and while sales have now dropped below that ﬁgure, its
market continues to grow. It is a ﬂuorinated nucleoside1e6 prodrug,
undergoing intracellular phosphorylation to its active diphosphate
and triphosphate form, which inhibits DNA synthesis leading to
apoptosis.7e11
The synthesis of gemcitabine12 has been subject to tremendous
anddspurred by the Lilly patent expirydstill continuing efforts.13
In general, a convergent synthesis has been applied, in which a
suitably protected and activated 2-deoxy-2,2-diﬂuororibofuranose
derivative 2 (Scheme 1) is combined with an activated cytosine
base, e.g. 3. Much optimisation has been devoted to an efﬁcient 2-
deoxy-2,2-diﬂuororibofuranose synthesis, a feat which has now
largely been achieved through use of speciﬁc alcohol protecting
groups allowing efﬁcient and high-yielding diastereomer separa-
tion by crystallisation(s). The nucleobase introduction reaction has
also been subject to intensive research. This process is made difﬁ-
cult by the diﬂuorination at the sugar 2-position, and typically leadslau).
r Ltd. This is an open access articleto an anomeric mixture. Again, selective crystallisation procedures
have been developed to obtain anomerically pure gemcitabine.13
While alternative linear nucleoside syntheses are common in
the carbanucleoside ﬁeld,14e16 this strategy has to our knowledge
been applied only once for the gemcitabine synthesis
(Scheme 2a).17
Here the sugar donor 5 was reacted with the N-2-cyanovinyl
amide 4 to give the intermediate 6, after which the cytosine syn-
thesis was completed by base-induced cyclisation. An overall yield
of 12% was reported. A linear synthesis is also possibledbut not
reporteddfrom the corresponding amino-2-deoxy-2,2-
diﬂuoroglycoside 9, which has been synthesised in two steps by a
Lilly group18 (Scheme 2b). However, while 9 was obtained in high
yield, no anomeric selectivity was obtained, and the anomeric ratio
of 9was independent of the anomeric ratio of the azide precursor 8,
suggesting an equilibration process.
Herein we describe our efforts leading to an alternative linear
gemcitabine synthesis. In order to avoid the abovementionedunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Scheme 2. Linear gemcitabine synthesis.
K. Brown et al. / Carbohydrate Research 406 (2015) 71e7572anomerisation at the aminoglycoside stage, a nucleobase con-
struction strategy starting from the corresponding glycosyl urea 10
was envisioned (Scheme 3). It was hoped that the possible crys-
tallinity of this urea derivative would offer anomeric puriﬁcation
prospects.1
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Scheme 3. Retrosynthetic analysis.In addition, it was planned to introduce the urea by a direct
condensation reaction with the known 3,5-di-O-benzoyl-2-deoxy-
2,2-diﬂuororibose 11, thus bypassing the need for anomeric acti-
vation. This protected diﬂuororibose derivative was ﬁrst described
by a Lilly group,19 but obtained by us by reduction of the
commercially available dibenzoylated diﬂuororibonolactone.Table 1
Optimisation of the urea condensation reaction
Entry Lactol 13 (equiv) Solvent PTSA (equiv) Dryi
1 12 b (2) Toluene 0.05 MS
2 12 b (2) Toluene 0.05 d
3 12 b (1) Toluene 0.05 d
4 12 b (1) Toluene 0.05 MS
5 11 b (3.3) Toluene 1.1 MS
6 11 a (3) Dioxane 1 MS
7 11 a (5) Dioxane 1 MS
8 11 a (3) Dioxane 1 Na2S
9 11 a (3) Dioxane 1 Na2S
10 11 a (5) Dioxane 1 Na2S
11 11 a (3) Dioxane 1 Na2S
12 11 a (3) Dioxane 1 Na2S
13 11 a (3) Dioxane 1 d
14 11 a (5) Dioxane 1 Na2S
15e 11 a (3) Dioxane 1 Na2S
a Isolated yield.
b Remove reaction solvent by evaporation in vacuo.
c Filtration over silica.
d Filtration over Celite.
e 2.3 mmol scale.2. Results and discussion
2.1. Urea condensation
The work commenced by investigating the direct urea intro-
duction. The acid-catalysed condensation of aldehydes with urea
has been reported in high yields,20,21 and there were few reports
available of this process with unprotected (and unﬂuorinated)
carbohydrates.22,23 In recent years, the reaction of unprotected and
non-activated carbohydrates with ureas has received renewed
attention, and has typically been achieved with an acid-catalyst.24
Hence, it was ﬁrst investigated whether the acid-catalysed
condensation of a diﬂuorinated sugar such as furanose 11 was
possible with ureas. Initially, the 5-O-TBDPS lactol 12 was used as
substrate (Table 1), and to avoid complication by the urea reacting
at both ends, N,N-dimethyl urea 12 was used.
Reaction of 12with 13b using a variety of acid catalysts (TMSOTf,
Ti(Oi-Pr)4, 4 N HCl, AcOH, TFA, p-TsOH) in a range of solvents (THF,
DCM, toluene, triﬂuoroethanol, hexaﬂuoroisopropanol) all gave no
or only trace amounts of product 14 (not shown), except the
combination of p-TsOH and toluene at reﬂux (entry 1). While, when
using 2 equiv of urea the presence/absence of molecular sieves had
no signiﬁcant inﬂuence (entries 1, 2), when 1 equiv of urea was
used, the use of molecular sieves did lead to a higher yield (entries
3, 4). Due to the possible lability of the TBDPS ether in acidic me-
dium, further optimisation experiments were carried out with the
3,5-di-O-benzoyl-2-deoxy-2,2-diﬂuororibose 11, obtained by
reduction of the commercially available lactone. Indeed, reaction
with 13b nowgave amuch improved 65% yield (entry 5), although a
further increase in amount of urea was used. At this stage, it was
decided to investigate the non-methylated urea 13a, which turned
out to be unproblematic with regard to a sequential condensation
process. The best solvent proved to be 1,4-dioxane (entry 6), giving
a yield of 40%, with 39% recovered starting material, when usingng agent Time (h) Work-up Et3N Column? Yielda (%)
18 b N 17
5.5 b N 22
5 b N 29
5.5 b N 38
20 c Y 65
18 Aqueous Y 40
44 Aqueous Y 59
O4 18 Aqueous Y 61
O4 36 Column Y 62
O4 72 Aqueous Y 64
O4 66 c Y 65
O4 36 d N 79
36 d N 76
O4 36 d N 79
O4 36 d N 88
K. Brown et al. / Carbohydrate Research 406 (2015) 71e75 731 equiv of p-TsOH. An increase in the relative amount of urea
increased the yield to 59% (entry 7). As good conversion was seen
by NMR analysis of crude material, losses during the workup due to
difﬁcult ﬁltration of the molecular sieves were thought to be
responsible for the reduced yield. However, a change of drying
agent to Na2SO4 (entries 8e11), whilst facilitating the work-up, did
not have a signiﬁcant effect upon the yield, regardless of urea
stoichiometry. Changing theworkup to ﬁltration over Celite instead
of silica gel did improve the yield (entry 12), though, surprisingly,
the reaction without Na2SO4 worked equally well (entry 13).
Increasing the number of urea equivalents to 5 had no further
beneﬁcial effect (entry 14). Finally, reaction on 2.3 mmol scale
under the best conditions led to an excellent 88% yield (entry 15) of
the glycosyl ureas in a 1:1.8 anomeric ratio. Unfortunately, assign-
ment of the anomers could not be achieved.
2.2. Formation of the cytosine nucleobase
Next, acylation of the urea group with acyl chloride 16, syn-
thesised by the method of Tietze,25 to give the nucleobase cycli-
sation precursor was investigated. Interestingly, this glycosyl urea
acylation does not have a precedent for O-nucleosides, but has been
demonstrated with carbanucleosides using pyridine with
DMAP.26,27 However, reaction of 14a with 16 under those condi-
tions (Table 2, entry 1), only afforded 30% of the desired product 17.
Unexpectedly, signiﬁcant anomerisation was observed, which led
to a decrease in anomeric ratio (1:2.4 to 1:1). This anomerisation
may be due to urea deprotonation by pyridine (Scheme 4), facili-
tated by the electron withdrawing ﬂuorines at the 2-position, to
give the conjugate base 18. Anomerisation can then be envisaged by
ring opening to 19 followed by non-selective ring closure.Table 2
Optimisation of the urea acylation reaction
O
BzO
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F
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14a
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N NH
EtO
O
OOEtO
Cl16
17
O
NH2
Entry Equiv
16
Reagents Solvent Temp
(C)
Time Yielda Anomeric
ratiob
1 1.5 0.25 equiv
DMAP
Pyridine Reﬂux 40 h 30% 1:1
2 1 1 equiv DMAP DCM RT 3.5 d 0% d
3 2 None MeCN Reﬂux 18 h 45% 1:1.5
4 4 None MeCN Reﬂux 18 h 71% 1:1.5
5 4 None Dioxane Reﬂux 18 h 61% 1:1.15
6 3 0.25 equiv
ZnCl2
CHCl3 Reﬂux 24 h 45% 1:1.9
a Isolated yield.
b Determined by NMR analysis on the crude reaction mixture.
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Scheme 4. Possible anomThus, the basic pyridine solvent was replaced by DCM, but even
with 1 equiv of DMAP, none of the desired product was observed
after 3.5 d (entry 2). Pleasingly, reﬂuxing in acetonitrile with
2 equiv of 16 (entry 3) did yield the product in 45% yield, with a
further improvement to 71% seen when the amount of 16 was
increased to 4 equiv (entry 4). These conditions also resulted in less
anomerisation (1:2.4 to 1:1.5). The same conditions with 1,4-
dioxane as solvent gave a slightly lower yield, but more anomer-
isation was observed (entry 5). The least anomerisation was seen
when ZnCl2 was employed, with a 1:1.9 anomeric ratio seen in the
isolated product (entry 6), but a lower yield was obtained.
With the acyl carbamate 17 in hand, cyclisation to the protected
diﬂuorouridine 20 was studied (Scheme 5) using methodology
originally developed by Shaw.28 Among the various acidic protocols
screened, HCl/AcOH emerged as the most efﬁcient, leading to
quantitative conversion to 20 in a 1:1.2 a/b mixture. Next, conver-
sion of uridine to cytidine was effected using described method-
ology29,30 via the triazole intermediate 21 by treatment with 2-
chlorophenyl phosphorodichloridate and 1,2,4-triazole in pyri-
dine, followed by reaction with ammonia. The ammonia treatment
also caused concomitant benzoate deprotection, which then fur-
nished gemcitabine 1 as a 1:1.3 mixture of a:b anomers.Scheme 5. Conversion to gemcitabine 1 via the corresponding uridine 20.3. Conclusion
The linear synthesis of gemcitabinewas achieved in 5 steps from
a 2-deoxy-2,2-diﬂuororibose substrate with moderate anomeric
selectivity. The demonstration of a high-yielding direct glycosyl
urea formation through reaction of a reducing 2-deoxy-2,2-
diﬂuorinated sugar derivative with urea will be of interest for
other applications.
4. Experimental section
4.1. Synthesis of the urea derivative 14a
Lactol 11 (870mg, 2.30mmol), urea (3 equiv, 6.90mmol, 414mg),
PTSA (1 equiv, 2.30 mmol, 437 mg) and Na2SO4 (2 equiv, 4.60 mmol,
653 mg) were stirred in 1,4-dioxane (6.5 mL) at reﬂux for 36 h. The
reaction mixture was cooled to RT, diluted with DCM and ﬁltered
through Celite. The solvents were reduced in vacuo to yield a crude
residue, which was puriﬁed by column chromatography on silica gelH
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erisation mechanism.
K. Brown et al. / Carbohydrate Research 406 (2015) 71e7574(10:90/40:60 acetone/petrol) to yield the desired glycosylurea 14a
as awhite foam, as a 1:1.8 anomeric mixture (853 mg, 88%). IR (ﬁlm)
3366(br), 2925 (w),1723 (m),1678 (m),1266 (s) cm1.LRMS (ESIþ)m/
z 443.2 (MþNa)þ (100). HRMS (ESIþ) for C20H18F2N2O6 (MþNa)þ
calcd 443.1025, found 443.1018.1HNMR (400MHz, CDCl3) d8.04 (4H,
m, 4CHAr), 7.61e7.33 (6H, m, 6CHAr), 6.69 (2/3H, d, J¼10.0 Hz,
NHMajor), 6.54 (1/3H, d, J¼8.8 Hz, NHMinor), 5.94 (1/3H, q, J¼8.2 Hz,
CHNHMinor), 5.78 (2/3H, ddd, J¼14.4, 10.1, 5.4 Hz, CHNHMajor), 5.67
(1/3H, ddd, J¼11.5, 8.1, 6.6Hz, CHOBzMinor), 5.46 (2/3H,m, CHOBzMajor),
5.34 (2/3H, br s, NH2Minor), 5.32 (4/3H, br s, NH2Major), 4.65e4.51 (7/3H,
m, CHCH2Minor, CH2), 4.36 (2/3H, q, J¼4.3 Hz, CHCH2Major) ppm. 13C
NMRþDEPT (100MHz,CDCl3) d166.3 (C]O),165.0 (C]OMajor),164.9
(C]OMinor), 157.8 (C]OMinor), 157.7 (C]OMajor), 134.0 (CHAr), 133.9
(CHAr), 133.3 (CHAr), 130.0 (CHAr), 129.7 (CHAr), 129.2 (CAr), 128.6
(CHAr), 128.5 (CHAr), 128.43 (CHAr), 128.38 (CHAr), 128.1 (CAr), 121.4
(dd, J¼262.4, 257.6 Hz, CF2Minor), 120.4 (dd, J¼266.3, 253.7 Hz,
CF2Major), 81.9 (dd, J¼37.9,19.4Hz, CHNMinor), 81.2 (dd, J¼34.0, 20.4Hz,
CHNMajor), 77.2 (d, J¼5.8 Hz, CHCH2Minor), 76.0 (CHCH2Major), 72.3 (dd,
J¼31.1, 17.5 Hz, CHOBzMinor), 72.0 (dd, J¼36.0, 16.5 Hz, CHOBzMajor),
63.4 (CH2Minor), 63.3 (CH2Major) ppm (some CHAr overlap).
Major Anomer: 19F NMR (282 MHz, CDCl3) d 117.9 (1F, dt,
J¼246.6, 14.7 Hz, CFF), 122.9 (1F, dd, J¼247.4, 5.2 Hz, CFF) ppm.
Minor Anomer: 19F NMR (282 MHz, CDCl3) d 113.2 (1F, d,
J¼243.1 Hz, CFF), 125.1 (1F, dt, J¼244.0, 7.8 Hz, CFF) ppm.
4.2. Synthesis of the N,N-dimethyl urea derivative 14b
To lactol 11 (35 mg, 0.09 mmol) in toluene (1 mL) was added 3 Å
molecular sieves (53 mg), N,N-dimethylurea (3 equiv, 0.30 mmol,
27 mg) and PTSA (1 equiv, 0.09 mmol, 19 mg). The reaction mixture
was stirred at reﬂux for 20 h then cooled to RTand dilutedwith DCM
before ﬁltration through a plug of silica (pre-treated with Et3N),
NaHCO3 and NaSO4. The solvents were reduced in vacuo to yield a
crude residue, which was puriﬁed by column chromatography on
silica gel (15:85/25:75 acetone/hexaneþ0.5% Et3N) to yield the
desiredglycosylurea14basanoil, asa1:2.7anomericmixture (27mg,
65%). IR (ﬁlm) 3307 (br), 2923 (w), 2853 (w),1724 (s),1659 (m),1522
(m), 1266 (s), 1095 (s) cm1. LRMS (ESIþ)m/z 919.5 (2MþNa)þ (100),
471.1 (MþNa)þ (71). HRMS (ESIþ) for C22H22F2N2O6 (MþNa)þ calcd
471.1338, found 471.1342.1HNMR (400MHz, CDCl3) d 8.09e8.03 (4H,
m, 4CHAr), 7.65e7.39 (6H, m, 6CHAr), 6.12 (0.25H, q, J¼8.2 Hz,
CHNMinor), 5.89 (0.75H, ddd, J¼14.9, 9.9, 5.2 Hz, CHNMajor), 5.72
(0.25H, ddd, J¼10.1, 8.3, 5.8 Hz, CHOBzMinor), 5.51 (0.75H, dd, J¼15.6,
5.0 Hz, CHOBzMajor), 5.41 (0.25H, d, J¼9.5 Hz, NHMinor), 5.28 (0.75H, d,
J¼9.8 Hz, NHMajor), 4.67e4.56 (2.25H, m, CH2OBz, CHCH2Minor), 4.40
(0.75H, q, J¼4.4 Hz, CHCH2Major), 2.98 (6H, br s, N(CH3)2) ppm. 13C
NMRþDEPT (100 MHz, CDCl3) d 166.0 (PhC]O), 164.9 (PhC]O),
156.0 (NHC]O), 134.02 (CHAr), 133.98 (CHAr), 133.3 (CHAr), 130.0
(CHAr), 129.9 (CHAr), 129.8 (CHAr), 129.4 (CHAr), 129.3 (CHAr), 128.6
(CHAr), 128.4 (CHAr), 128.3 (CHAr), 128.2 (2CAr), 82.1 (dd, J¼36.9,
18.5 Hz, CHNMinor), 81.6 (dd, J¼34.0, 19.4 Hz, CHNMajor), 77.1
(CHCH2Minor), 76.2 (t, J¼2.9 Hz, CHCH2Major), 72.6 (dd, J¼31.1, 17.5 Hz,
CHOBzMinor), 72.0 (dd, J¼36.0, 17.5 Hz, CHOBzMajor), 63.8 (CH2Minor),
63.3 (CH2Major), 36.3 (N(CH3)2Major), 36.2 (N(CH3)2Minor) ppm (some
CHAr overlap, CF2 not visible).
Major anomer: 19F NMR (282 MHz, CDCl3) d 118.4 (1F, dt,
J¼247.1, 15.0 Hz, CFF), 123.3 (1F, dd, J¼247.1, 5.4 Hz, CFF) ppm.
Minor anomer: 19F NMR (282 MHz, CDCl3) d 114.9 (1F, dt,
J¼243.9, 9.7 Hz, CFF), 126.4 (1F, dt, J¼242.8, 8.6 Hz, CFF) ppm.
4.3. Synthesis of the N,N-dimethyl urea derivative 15b
To lactol 12 (102 mg, 0.20 mmol) in toluene (0.8 mL) was added
N,N-dimethylurea (1 equiv, 0.16 mmol, 18 mg), a catalytic amount
of PTSA and molecular sieves (90 mg). The reaction mixture wasstirred at reﬂux for 5.5 h, cooled to RT and the solvents removed in
vacuo to yield a crude residue. This residue was ﬁrst puriﬁed by
column chromatography on silica gel (10:90 acetone/hexane) fol-
lowed by HPLC (10:90 acetone/hexane) to yield 15b as a colourless
oil as a 1:2.9 anomeric mixture (44 mg, 38%). IR (ﬁlm) 3070 (w),
2930 (m), 2857 (m), 1472 (m), 1456 (m) cm1.
Major anomer: 1H NMR (400 MHz, acetone-d6) d 7.76e7.67 (4H,
m, 4ArH), 7.49e7.31 (11H, m, 11ArH), 4.87 (1H, d, J¼11.8 Hz,
OCHHPh), 4.66 (1H, d, J¼11.6 Hz, OCHHPh), 4.63 (1H, m, CHN), 4.23
(1H, ddd, J¼12.3, 11.2, 8.3 Hz, CHOBn), 3.97 (1H, m, CHCH2OSi), 3.84
(1H, dd, J¼11.6, 3.5 Hz, CHHOSi), 3.75 (1H, m, CHHOSi), 2.47 (6H, s,
N(CH3)2), 1.01 (9H, s, C(CH3)3) ppm (NH not visible). 13C
NMRþDEPT (100 MHz, acetone-d6) d 182.2 (C]O), 138.6 (CAr),
136.5 (2CHAr), 134.1 (2CAr), 130.84 (2CHAr), 130.76 (2CHAr),
129.3 (2CHAr), 128.8 (5CHAr), 128.7 (2CHAr), 125.1 (dd, J¼259.5,
255.1 Hz, CF2), 96.6 (dd, J¼31.8, 24.3 Hz, CHN), 81.7 (CHCH2), 77.7
(m, CHOBn), 73.3 (CH2), 63.3 (CH2), 41.0 (N(CH3)2), 27.3 (C(CH3)3),
19.9 (C(CH3)3) ppm. 19F NMR (376 MHz, acetone-d6) d 112.3 (1F,
ddd, J¼240.3, 14.3, 11.0 Hz, CFF), 113.0 (1F, dt, J¼240.3, 11.8 Hz,
CFF) ppm.
Minor anomer: 1H NMR (400 MHz, acetone-d6) d 7.76e7.67 (4H,
m, 4ArH), 7.49e7.31 (11H, m, 11ArH), 4.86 (1H, d, J¼11.9 Hz,
OCHHPh), 4.74 (1H, t, J¼11.1 Hz, CHN), 4.65 (1H, d, J¼11.7 Hz,
OCHHPh), 4.39 (1H, ddd, J¼12.2, 9.2, 7.1 Hz, CHOBn), 4.09 (1H, dtd,
J¼6.9, 3.4, 1.3 Hz, CHCH2OSi), 3.86 (1H, m, CHHOSi), 3.76 (1H, m,
CHHOSi) 2.44 (6H, s, N(CH3)2), 1.02 (9H, s, C(CH3)3) ppm (NH not
observed). 13C NMRþDEPT (100 MHz, acetone-d6) d 182.2 (C]O),
138.6 (CAr), 136.5 (2CHAr), 134.0 (2CAr), 130.9 (2CHAr), 130.8
(2CHAr), 129.4 (2CHAr), 128.8 (5CHAr), 128.7 (2CHAr), 96.1 (dd,
J¼36.4, 18.0 Hz, CHN), 81.6 (CHCH2), 77.9 (m, CHOBn), 73.4 (CH2),
64.4 (CH2), 41.4 (N(CH3)2), 27.3 (C(CH3)3), 19.9 (C(CH3)3) ppm (CF2
not observed). 19F NMR (376 MHz, acetone-d6) d 105.4 (1F, dt,
J¼240.8, 11.8 Hz, CFF), 126.4 (1F, dt, J¼240.3, 11.0 Hz, CFF) ppm.
4.4. Synthesis of 17
To glycosylurea 14a (93 mg, 0.22 mmol) stirring at reﬂux in
MeCN (0.6 mL) was added dropwise a solution of acyl chloride 16
(4 equiv, 0.88 mmol, 119 mg) in MeCN (0.4 mL). The reaction
mixture was stirred at reﬂux for 18 h, then quenched with water
(0.1 mL). The solvents were reduced in vacuo to yield a crude res-
idue, which was taken up in DCM (15 mL), washed with water
(5 mL), then brine and dried over anhydrous MgSO4. The solvents
were reduced in vacuo to yield a crude residue, which was puriﬁed
by ﬂash chromatography on silica gel (10:90/40:60 acetone/
petrol) to yield the desired product 17 as a colourless oil as a 1:1.5
mixture of anomers (82mg, 71%). IR (ﬁlm) 3246 (br), 2981 (w),1717
(s), 1680 (s), 1603 (m), 1537 (s), 1492 (w), 1452 (m), 1378 (w), 1316
(m), 1247 (s), 1176 (m), 1093 (s) cm1. LRMS (ESIþ) m/z 1059.8
(2MþNa)þ (50), 541.3 (MþNa)þ (100). HRMS (ESIþ) for
C25H24F2N2O8 (MþNa)þ Calcd: 541.1393; Found: 541.1411. 1H NMR
(400MHz, CDCl3) d 10.01 (0.5H, d, J¼9.2 Hz, 0.5CHNH), 9.79 (0.5H,
d, J¼9.5 Hz, 0.5CHNH), 9.65 (0.5H, s, 0.5O]CNHC]O), 9.28
(0.5H, s, 0.5O]CNHC]O), 8.22e8.20 (1H, m, CHAr), 8.08e8.02
(3H, m, 3CHAr), 7.69 (1H, d, J¼11.9 Hz, HC¼CHOEt), 7.65e7.40 (6H,
m, 6CHAr), 6.08 (0.5H, t, J¼9.3 Hz, 0.5CHN), 5.90 (0.5H, ddd,
J¼12.9, 9.5, 6.0 Hz, 0.5CHN), 5.70e5.67 (0.5H, m, 0.5CHOBn),
5.57 (0.5H, ddd, J¼14.7, 5.1, 1.0 Hz, 0.5CHOBn), 5.37 (0.5H, d,
J¼12.1 Hz, 0.5CHOEt), 5.34 (0.5H, d, J¼12.0 Hz, 0.5CHOEt),
4.69e4.58 (2.5H, m, CHCH2, 0.5CHCH2), 4.43 (0.5H, q, J¼4.5 Hz,
0.5CHCH2), 3.98 (2H, q, J¼7.1 Hz, CH2CH3), 1.34 (1.5H, t, J¼7.0 Hz,
0.5CH3), 1.33 (1.5H, t, J¼7.1 Hz, 0.5CH3) ppm. 13C NMRþDEPT
(100MHz, CDCl3) d 168.3 (0.5C]OCH]CH),168.1 (0.5C]OCH]
CH), 166.07 (0.5PhCOCH2), 166.05 (0.5PhCOCH2), 164.9
(0.5PhCOCH),164.7 (0.5PhCOCH),164.0 (0.5CH]CHOEt),163.6
K. Brown et al. / Carbohydrate Research 406 (2015) 71e75 75(0.5CH]CHOEt), 155.1 (0.5NC]ON), 154.9 (0.5NC]ON), 134.0
(CHAr), 133.3 (CHAr), 133.2 (CHAr), 130.4 (CHAr), 130.0 (CHAr), 129.8
(CHAr), 128.6 (CHAr), 128.5 (CHAr), 128.4 (CHAr), 129.33 (0.5CAr),
129.30 (0.5CAr), 128.2 (0.5CAr), 128.0 (0.5CAr), 97.5 (HC]
CHOEt), 81.2 (dd, J¼39.5, 22.0 Hz, 0.5CHN), 80.5 (dd, J¼36.6,
22.0 Hz, 0.5CHN), 79.3 (0.5CHCH2), 76.7 (0.5CHCH2), 72.2 (dd,
J¼33.7, 17.6 Hz, 0.5CHOBz), 72.0 (dd, J¼35.1, 17.6 Hz, 0.5CHOBz),
68.0 (0.5CH2CH3), 67.7 (0.5CH2CH3), 63.3 (0.5CHCH2), 63.2
(0.5CHCH2), 14.43 (0.5CH3), 14.36 (0.5CH3) ppm (some CHAr
overlap, CF2 not visible). 19F NMR (282 MHz, CDCl3) d Anomer
1: 109.5 (1F, ddd, J¼251.4, 16.1, 6.4 Hz, CFF), 125.4 (1F, d,
J¼252.5 Hz, CFF) ppm; Anomer 2: 123.6 (1F, dd, J¼241.8, 9.7 Hz,
CFF),125.5 (1F, ddd, J¼241.8,10.7, 6.4 Hz, CFF) ppm. (Data assigned
from an earlier experiment, which gave a 1:1 mixture of anomers).
4.5. Synthesis of the uridine 20
Acyl carbamate 17 (136 mg, 0.26 mmol) was stirred in 1:10 HCl/
AcOH (2.75 mL) at RT in a stoppered ﬂask for 24 h. The solvents
were reduced in vacuo to yield the desired protected diﬂuorouracil
20 as a yellow oil as a 1:1.2 a/b mixture of anomers (125 mg,
quantitative yield).
1H NMR (400 MHz, CDCl3) d 8.91 (1H, br s, NH), 8.11e8.02 (4H,
m, CHAr), 7.69e7.39 (7H, m, 6CHAr, NCH]CH), 6.55 (0.45H, t,
J¼7.5 Hz, CHNa), 6.40 (0.55H, dd, J¼11.8, 6.4 Hz, CHNb), 5.82 (0.45H,
d, J¼8.1 Hz, NCH]CHa), 5.79 (0.45H, m, CHOBza), 5.68 (0.55H, d,
J¼8.3 Hz, NCH]CHb), 5.65 (0.55H, m, CHOBzb), 4.89e4.81 (1H, m,
CHCHH), 4.73e4.59 (2H, m, CHO, CHCHH) ppm. 19F NMR (282 MHz,
CDCl3) d 109.2 (0.45F, d, J¼249.3 Hz, CFF), 115.5 (0.55F, dt,
J¼247.4, 12.9 Hz, CFF), 120.3 (0.5F, d, J¼246.6 Hz, CFF), 122.0
(0.5F, d, J¼250.9 Hz, CFF) ppm.
4.6. Synthesis of gemcitabine 1
To crude protected diﬂuorouridine 20 (378 mg, 0.75 mmol) in
pyridine (9 mL) was added 1,2,4-triazole (3 equiv, 2.26 mmol,
156 mg) and 2-chlorophenyl phosphorodichloridate (6 equiv,
4.51 mmol, 0.74 mL). The reaction mixture was stirred at RT for 5 d.
The solvents were reduced in vacuo to yield a crude residue, which
was taken up in DCM and washed with satd NaHCO3 (aq), then
brine and dried over anhydrous Na2SO4. The solvents were reduced
in vacuo to yield a crude oil, whichwas passed through a short silica
column (10:90 acetone/petrol) to yield the impure triazole 21
(94 mg, ~24%). This triazole (76.5 mg, 0.17 mol) was stirred in 7 N
NH3 in MeOH (5 mL) at RT for 36 h. The solvents were reduced in
vacuo and the resultant residue evaporated onto silica gel for pu-
riﬁcation by column chromatography (10:90e20:80 MeOH/DCM)
to yield the desired diﬂuorocytidine 1 as a 1:1.3 a/b mixture of
anomers (18.7 mg, 49%). 1H NMR (400 MHz, DMSO-d6) d 7.69 (0.6H,
d, J¼7.6 Hz, NCH]CHb), 7.52 (0.4H, dd, J¼7.5, 1.6 Hz, NCH]CHa),
7.37e7.30 (2H, m, NH2), 6.30e6.26 (0.8H, m, CHNa, CHOHa), 6.22
(0.6H, d, J¼6.6 Hz, CHOHb), 6.13 (0.6H, t, J¼8.3 Hz, CHNb), 5.79 (0.4H,
d, J¼7.5 Hz, NCH]CHa), 5.78 (0.6H, d, J¼7.6 Hz, NCH]CHb), 5.19
(0.6H, t, J¼5.4 Hz, CH2OHb), 5.07 (0.4H, t, J¼5.7 Hz, CH2OHa), 4.34
(0.4H, m, CHOHa), 4.18e4.07 (1.2H, m, CHOHb, CHCH2(b)), 3.81e3.74(1H, m, CHCH2a, CHCHHb), 3.64e3.59 (1H, m, CHCHH), 3.53 (0.4H,
m, CHCHHa) ppm. 13C NMRþDEPT (100 MHz, DMSO-d6) d 165.7
(0.5NCON), 165.6 (0.5NCON), 154.8 (0.5N]C), 154.7 (0.5N]
C), 141.3 (0.5NC]C), 140.8 (0.5NC]C), 123.1 (t, J¼252.6 Hz, CF2),
94.6 (0.5NC]C), 94.4 (0.5NC]C), 83.9e83.2 (m, CHN), 80.4
(CHCH2), 69.6 (dd, J¼26.3, 17.6 Hz, 0.5CHOH), 68.7 (t, J¼22.0 Hz,
CHOH), 60.0 (0.5CH2), 59.0 (0.5CH2) ppm. 19F NMR (282 MHz,
DMSO-d6) d 114.3 (0.4F, d, J¼232.8 Hz, CFFa), 115.5 to 117.3
(1.2F, m, CF2(b)), 124.3 (0.4F, d, J¼234.5 Hz, CFFa) ppm.
Data consistent with the literature.12Acknowledgements
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